Skip to main content
. 2021 Feb 25;10:600573. doi: 10.3389/fonc.2020.600573

Table 5.

PD1/PD-L1 antibody-NK cell combination treatment in advanced or metastatic TNBC.

NCT Number Other IDs Intervention Trial status Ref
NCT04551885 FT516-102 Avelumab + FT-516 Recruiting
NCT03387085 QUILT-3.067 Avelumab + haNK + IL-15 + vaccine + chemoradiation Active
ORR 67%
PFS (13.7 mths)
(156)

FT-516, iPSC-derived NK cells with hnCD16; IL-15, interleukin 15; NK, natural killer cell; ORR, overall response rate; PFS, progression free survival.